A detailed history of Victory Capital Management Inc transactions in Incyte Corp stock. As of the latest transaction made, Victory Capital Management Inc holds 187,261 shares of INCY stock, worth $11.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
187,261
Previous 175,938 6.44%
Holding current value
$11.4 Million
Previous $11 Million 3.43%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$56.55 - $66.59 $640,315 - $753,998
11,323 Added 6.44%
187,261 $10.7 Million
Q4 2023

Feb 05, 2024

BUY
$52.16 - $64.19 $527,598 - $649,281
10,115 Added 6.1%
175,938 $11 Million
Q3 2023

Nov 06, 2023

BUY
$57.77 - $65.93 $1.72 Million - $1.96 Million
29,761 Added 21.87%
165,823 $9.58 Million
Q2 2023

Jul 27, 2023

SELL
$60.95 - $75.51 $839,342 - $1.04 Million
-13,771 Reduced 9.19%
136,062 $8.47 Million
Q1 2023

May 02, 2023

SELL
$70.23 - $86.01 $1.21 Million - $1.48 Million
-17,206 Reduced 10.3%
149,833 $10.8 Million
Q4 2022

Feb 10, 2023

BUY
$67.18 - $84.11 $1.59 Million - $1.98 Million
23,598 Added 16.45%
167,039 $13.4 Million
Q4 2022

Feb 09, 2023

SELL
$67.18 - $84.11 $9.33 Million - $11.7 Million
-138,901 Reduced 49.2%
143,441 $11.5 Million
Q3 2022

Nov 02, 2022

SELL
$66.18 - $82.86 $3 Million - $3.76 Million
-45,385 Reduced 13.85%
282,342 $18.8 Million
Q2 2022

Aug 01, 2022

BUY
$66.18 - $83.18 $11.7 Million - $14.7 Million
176,262 Added 116.37%
327,727 $24.9 Million
Q1 2022

May 04, 2022

BUY
$66.02 - $79.71 $2.92 Million - $3.53 Million
44,303 Added 41.34%
151,465 $11.4 Million
Q4 2021

Feb 07, 2022

SELL
$63.34 - $74.11 $3.36 Million - $3.93 Million
-53,029 Reduced 33.1%
107,162 $7.87 Million
Q3 2021

Nov 02, 2021

BUY
$68.67 - $84.02 $2.81 Million - $3.44 Million
40,990 Added 34.39%
160,191 $11 Million
Q2 2021

Aug 03, 2021

BUY
$79.87 - $87.53 $29,551 - $32,386
370 Added 0.31%
119,201 $10 Million
Q1 2021

May 04, 2021

SELL
$76.02 - $100.5 $163,366 - $215,974
-2,149 Reduced 1.78%
118,831 $9.66 Million
Q4 2020

Feb 01, 2021

SELL
$80.74 - $97.7 $226,072 - $273,560
-2,800 Reduced 2.26%
120,980 $10.5 Million
Q3 2020

Nov 09, 2020

SELL
$85.07 - $109.69 $13.6 Million - $17.5 Million
-159,606 Reduced 56.32%
123,780 $11.1 Million
Q2 2020

Aug 07, 2020

SELL
$74.18 - $108.93 $333,142 - $489,204
-4,491 Reduced 1.56%
283,386 $29.5 Million
Q1 2020

May 04, 2020

SELL
$63.18 - $85.97 $4.23 Million - $5.75 Million
-66,881 Reduced 18.85%
287,877 $21.1 Million
Q4 2019

Feb 06, 2020

BUY
$73.04 - $95.72 $754,941 - $989,361
10,336 Added 3.0%
354,758 $31 Million
Q4 2019

Feb 04, 2020

SELL
$73.04 - $95.72 $2.33 Million - $3.05 Million
-31,876 Reduced 8.47%
344,422 $25.2 Million
Q3 2019

Nov 12, 2019

BUY
$72.82 - $86.52 $8.91 Million - $10.6 Million
122,324 Added 48.16%
376,298 $27.9 Million
Q2 2019

Aug 15, 2019

SELL
$73.52 - $88.7 $7.04 Million - $8.49 Million
-95,733 Reduced 27.38%
253,974 $21.6 Million
Q1 2019

May 03, 2019

BUY
$63.56 - $88.17 $22.1 Million - $30.6 Million
347,105 Added 13339.93%
349,707 $30.1 Million
Q4 2018

Feb 05, 2019

SELL
$58.5 - $69.94 $994 - $1,188
-17 Reduced 0.65%
2,602 $165,000
Q3 2018

Nov 01, 2018

SELL
$61.75 - $74.23 $2,346 - $2,820
-38 Reduced 1.43%
2,619 $181,000
Q2 2018

Aug 02, 2018

SELL
$60.85 - $83.98 $7.55 Million - $10.4 Million
-124,043 Reduced 97.9%
2,657 $178,000
Q1 2018

May 04, 2018

BUY
$83.06 - $100.98 $3.1 Million - $3.77 Million
37,314 Added 41.74%
126,700 $10.6 Million
Q4 2017

Feb 01, 2018

BUY
$93.56 - $116.6 $940,465 - $1.17 Million
10,052 Added 12.67%
89,386 $8.47 Million
Q3 2017

Oct 27, 2017

SELL
$109.15 - $138.27 $36.7 Million - $46.5 Million
-336,080 Reduced 80.9%
79,334 $9.26 Million
Q2 2017

Aug 07, 2017

BUY
N/A
415,414
415,414 $52.3 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $13.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.